B. Riley analyst Mayank Mamtani raised the firm’s price target on TG Therapeutics to $23 from $17 and keeps a Buy rating on the shares after the FDA approved Briumvi for the treatment of relapsing forms of multiple sclerosis.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TGTX: